ProdigEye

Company Overview

Snapshot

Founded in February 2026 by Ron Ritter and Dr. Moshe Fisher, ProdigEye operates with 1–10 employees. The company is currently in the clinical validation and regulatory submission stages for its AI-based clinical decision support platform.

Business overview

ProdigEye develops an AI-based clinical decision support platform specifically for ophthalmology, focusing on anterior segment conditions. Its core technology analyzes eye images to assist licensed clinicians in their decision-making processes. The company is developing its product as Software as a Medical Device (SaMD) and operates within the Health Tech & Life Sciences sector, specifically targeting the Digital Healthcare and Medical Decision Support markets.

Company Intelligence Q&A

What is ProdigEye's primary focus in ophthalmology?

ProdigEye focuses on developing an AI-based clinical decision support platform for anterior segment eye conditions. The system analyzes eye images to aid licensed clinicians in their diagnostic processes.

What stage is ProdigEye's product development currently in?

ProdigEye's product is currently in the clinical validation and regulatory submission stages. The company indicates it is developing the product as Software as a Medical Device (SaMD).

Who are the founders of ProdigEye?

ProdigEye was co-founded by Ron Ritter, who serves as CEO, and Dr. Moshe Fisher, who holds the position of Chief Medical Officer.

When was ProdigEye founded?

ProdigEye was founded in February 2026.

What is the intended use of ProdigEye's AI platform?

ProdigEye's AI platform is intended to assist licensed clinicians in decision-making by analyzing eye images. Its outputs are designed to be reviewed by a qualified practitioner and not used as an autonomous diagnosis.